<DOC>
	<DOCNO>NCT02590367</DOCNO>
	<brief_summary>The purpose study estimate usefulness safety HD6610 granule oxaliplatin-induced peripheral neuropathy . The investigator examine efficacy safety treatment algorithm 64 patient colorectal cancer evaluate side effect degree improvement subjective symptom .</brief_summary>
	<brief_title>Estimate Efficacy HD6610 Granule Oxaliplatin-induced Peripheral Neuropathy</brief_title>
	<detailed_description>Oxaliplatin third generation platinum-based cytotoxic agent , widely use colorectal cancer , metastatic disease adjuvant setting . Moreover , oxaliplatin use alternative option cisplatin various cancer , ovarian , gastric . Oxaliplatin-induced peripheral neuropathy characterise acute transient cold hyperaesthesia hour day follow oxaliplatin infusion ( &gt; 90 % patient ) , also retard chronic neuropathy due repetition chemotherapy cycle ( 30-50 % patient ) . Oxaliplatin-induced peripheral neuropathy impairs health-related quality life ( HRQOL ) patient preventive curative strategy yet proven effective far . Animal experiment show HD6610 granule relieve mouse 's peripheral neuropathy induce oxaliplatin . In clinical practice , investigator also find HD6610 granule relieve patient 's oxaliplatin-induced peripheral neuropathy treatment chemotherapy . So investigators design randomize , parallel-group , double-blind , placebo-controlled , multicenter clinical study estimate efficacy safety HD6610 granule oxaliplatin-induced peripheral neuropathy colorectal cancer .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>1 . All case diagnose colorectal cancer pathology ; 2 . Patients receive chemotherapy receive oxaliplatinbased chemotherapy ( FOLFOX4 , FOLFOX6 , XELOX ) ; 3 . Patients 1870 year old serious heart , liver , kidney hematopoietic disfunction , life expectancy 3 month KPS 60 ; 4 . Patients positive sign neurological examination , drug allergy history diabetes ; 5 . Volunteered participate sign informed consent , patient receive radiotherapy , acupuncture moxibustion treatment experiment . 1 . Not accordant inclusion criterion ; 2 . Patients use herbal within 4 week registration ; 3 . Patients serious heart , liver , kidney hematopoietic disfunction ; 4 . Patients central nervous system disease ; 5 . Patients cervical spondylopathy , lumbar disc protrusion , diabetes uremia potentially cause peripheral neuropathy ; 6 . Nerve compression cause tumor metastasis peripheral neuropathy cause electrolyte disturbance , diabetes , alcohol disease disorder ; 7 . Longtime use thiazide diuretic foxglove ; 8 . Patients poison , infection radiotherapy induce peripheral neuropathy receive medicine cause peripheral neuropathy ; 9 . Patients hardly take Chinese Medicine severe diarrhea , vomit intestinal obstruction ; 10 . Uncontrolled psychosis ; 11 . Women pregnancy , prepare pregnant , lactation ; 12 . Alcohol drug abuse ; 13 . Allergic constitution allergy experiment drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>oxaliplatin-induced peripheral neuropathy</keyword>
	<keyword>HD6610 granule</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>